Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 76 articles: HTML format

Single Articles

March 2023
1. KLECZKO EK, Le AT, Hinz TK, Nguyen TT, et al
   Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response.
   Cancer Lett. 2023;556:216062.
   PubMed     Abstract available
   
   
   February 2023
2. YANG J, Hou C, Wang H, Perez EA, et al
   Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10.
   Cancer Lett. 2023;555:216025.
   PubMed     Abstract available
   
   
   November 2022
3. TANG B, Wang Y, Xu W, Zhu J, et al
   Macrophage-specific xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer.
   Cancer Lett. 2022 Nov 28:216021. doi: 10.1016/j.canlet.2022.216021.
   PubMed     Abstract available
   
   
   
4. TIAN Y, Xu L, Li X, Li H, et al
   SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
   Cancer Lett. 2022 Nov 27:216022. doi: 10.1016/j.canlet.2022.216022.
   PubMed     Abstract available
   
   
   October 2022
5. WANG Y, Wang Y, Yu J, Meng X, et al
   The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues.
   Cancer Lett. 2022 Oct 17:215947. doi: 10.1016/j.canlet.2022.215947.
   PubMed     Abstract available
   
   
   
6. MYACHEVA K, Walsh A, Riester M, Pelos G, et al
   CRISPRi screening identifies CASP8AP2 as an essential viability factor in lung cancer controlling tumor cell death via the AP-1 pathway.
   Cancer Lett. 2022 Oct 14:215958. doi: 10.1016/j.canlet.2022.215958.
   PubMed     Abstract available
   
   
   
7. PALAZZO A, Hernandez-Vargas H, Goehrig D, Medard JJ, et al
   Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells.
   Cancer Lett. 2022;546:215850.
   PubMed     Abstract available
   
   
   
8. ZHANG T, Zhang G, Chen X, Chen Z, et al
   Low-dose carbon monoxide suppresses metastatic progression of disseminated cancer cells.
   Cancer Lett. 2022;546:215831.
   PubMed     Abstract available
   
   
   September 2022
9. ZHANG C, Zhou L, Li S, Zhao J, et al
   Obesity accelerates immune evasion of non-small cell lung carcinoma via TFEB-dependent upregulation of Siglec-15 and glycolytic reprogramming.
   Cancer Lett. 2022 Sep 20:215918. doi: 10.1016/j.canlet.2022.215918.
   PubMed     Abstract available
   
   
   
10. CHEN TW, Hung WZ, Chiang SF, Chen WT, et al
    Dual inhibition of TGFbeta signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1.
    Cancer Lett. 2022;543:215795.
    PubMed     Abstract available
    
    
    
11. ZHANG P, Li B, Chen Q, Wang H, et al
    Glucose restriction induces ROS-AMPK-mediated CTR1 expression and increases cisplatin efficiency in NSCLC.
    Cancer Lett. 2022;543:215793.
    PubMed     Abstract available
    
    
    August 2022
12. HUANG H, Yang Y, Zhu Y, Chen H, et al
    Blood protein biomarkers in lung cancer.
    Cancer Lett. 2022 Aug 19:215886. doi: 10.1016/j.canlet.2022.215886.
    PubMed     Abstract available
    
    
    
13. BAHREYNI A, Liu H, Mohamud Y, Xue YC, et al
    A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
    Cancer Lett. 2022 Aug 19:215849. doi: 10.1016/j.canlet.2022.215849.
    PubMed     Abstract available
    
    
    
14. HU Y, Lu Y, Xing F, Hsu W, et al
    FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression.
    Cancer Lett. 2022 Aug 16:215867. doi: 10.1016/j.canlet.2022.215867.
    PubMed     Abstract available
    
    
    
15. ZHANG N, Gao Y, Huang Z, Dai P, et al
    PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy.
    Cancer Lett. 2022 Aug 1:215852. doi: 10.1016/j.canlet.2022.215852.
    PubMed     Abstract available
    
    
    July 2022
16. ZHAO W, Jin L, Chen P, Li D, et al
    Colorectal cancer immunotherapy-Recent progress and future directions.
    Cancer Lett. 2022 Jul 7:215816. doi: 10.1016/j.canlet.2022.215816.
    PubMed     Abstract available
    
    
    
17. SHANG C, Sun Y, Wang Y, Shi H, et al
    CXCL10 conditions alveolar macrophages within the premetastatic niche to promote metastasis.
    Cancer Lett. 2022;537:215667.
    PubMed     Abstract available
    
    
    June 2022
18. LI J, Zhang Q, Jiang D, Shao J, et al
    CircRNAs in lung cancer- role and clinical application.
    Cancer Lett. 2022 Jun 30:215810. doi: 10.1016/j.canlet.2022.215810.
    PubMed     Abstract available
    
    
    
19. YIN H, Wang X, Zhang X, Zeng Y, et al
    Corrigendum to "UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation" [Canc. Lett. 494 (2020) 121-131].
    Cancer Lett. 2022 Jun 16:215792. doi: 10.1016/j.canlet.2022.215792.
    PubMed    
    
    
    
20. CHEN B, Song Y, Zhan Y, Zhou S, et al
    Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway.
    Cancer Lett. 2022 Jun 11:215783. doi: 10.1016/j.canlet.2022.215783.
    PubMed     Abstract available
    
    
    
21. LI S, Qu Y, Liu L, Zhang X, et al
    Proteomic analysis of plasma-derived exosomes identifies biomarkers that distinguish brain and liver metastasis in lung cancer patients.
    Cancer Lett. 2022 Jun 9:215782. doi: 10.1016/j.canlet.2022.215782.
    PubMed     Abstract available
    
    
    
22. GAO J, Zhang LX, Ao YQ, Jin C, et al
    Elevated circASCC3 limits antitumor immunity by sponging miR-432-5p to upregulate C5a in non-small cell lung cancer.
    Cancer Lett. 2022;543:215774.
    PubMed     Abstract available
    
    
    May 2022
23. SUN Y, Sun H, Qi Y, Pan M, et al
    Ring finger protein 6 enhances chemo-resistance by transcriptionally activating proliferating cell nuclear antigen expression and attenuating DNA damage in lung adenocarcinoma.
    Cancer Lett. 2022;534:215609.
    PubMed     Abstract available
    
    
    
24. TIAN Y, Ma J, Jing X, Zhai X, et al
    Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy.
    Cancer Lett. 2022;541:215719.
    PubMed     Abstract available
    
    
    April 2022
25. LOU Y, Lu J, Zhang Y, Gu P, et al
    The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma.
    Cancer Lett. 2022;532:215599.
    PubMed     Abstract available
    
    
    
26. SHI Y, Xu Y, Xu Z, Wang H, et al
    TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression.
    Cancer Lett. 2022;532:215583.
    PubMed     Abstract available
    
    
    
27. TSENG PC, Chen CL, Lee KY, Feng PH, et al
    Epithelial-to-mesenchymal transition hinders interferon-gamma-dependent immunosurveillance in lung cancer cells.
    Cancer Lett. 2022 Apr 28:215712. doi: 10.1016/j.canlet.2022.215712.
    PubMed     Abstract available
    
    
    
28. TAROMI S, Firat E, Simonis A, Braun LM, et al
    Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer.
    Cancer Lett. 2022 Apr 26:215697. doi: 10.1016/j.canlet.2022.215697.
    PubMed     Abstract available
    
    
    
29. FU L, Deng R, Huang Y, Yang X, et al
    Corrigendum to "DGKA interacts with SRC/FAK to promote the metastasis of non-small cell lung cancer" [Canc. Lett. (2022 Apr 28) 532 215585].
    Cancer Lett. 2022 Apr 24:215696. doi: 10.1016/j.canlet.2022.215696.
    PubMed    
    
    
    
30. TAROMI S, Firat E, Simonis A, Braun LM, et al
    Retraction notice to "Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer" [Canc. Lett. 520 (2021) 385-399].
    Cancer Lett. 2022 Apr 20:215680. doi: 10.1016/j.canlet.2022.215680.
    PubMed     Abstract available
    
    
    
31. YAN R, Fan X, Xiao Z, Liu H, et al
    Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/beta-Catenin activity and cancer stemness.
    Cancer Lett. 2022;531:83-97.
    PubMed     Abstract available
    
    
    March 2022
32. WANG J, Wren JD, Ding Y, Chen J, et al
    EWI2 promotes endolysosome-mediated turnover of growth factor receptors and integrins to suppress lung cancer.
    Cancer Lett. 2022 Mar 23:215641. doi: 10.1016/j.canlet.2022.215641.
    PubMed     Abstract available
    
    
    February 2022
33. CHEN H, Zhao L, Meng Y, Qian X, et al
    Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression.
    Cancer Lett. 2022 Feb 28:215611. doi: 10.1016/j.canlet.2022.215611.
    PubMed     Abstract available
    
    
    
34. SCHREIBER C, Gruber A, Rosswag S, Saraswati S, et al
    Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.
    Cancer Lett. 2022 Feb 15:215600. doi: 10.1016/j.canlet.2022.215600.
    PubMed     Abstract available
    
    
    
35. YANG X, Zeng Z, Jie X, Wang Y, et al
    Arginine methyltransferase PRMT5 methylates and destabilizes Mxi1 to confer radioresistance in non-small cell lung cancer.
    Cancer Lett. 2022;532:215594.
    PubMed     Abstract available
    
    
    
36. FU L, Deng R, Huang Y, Yang X, et al
    DGKA interacts with SRC/FAK to promote the metastasis of non-small cell lung cancer.
    Cancer Lett. 2022 Feb 4:215585. doi: 10.1016/j.canlet.2022.215585.
    PubMed     Abstract available
    
    
    
37. WEI K, Ma Z, Yang F, Zhao X, et al
    M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942.
    Cancer Lett. 2022;526:205-216.
    PubMed     Abstract available
    
    
    
38. FISK JN, Mahal AR, Dornburg A, Gaffney SG, et al
    Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma.
    Cancer Lett. 2022;526:346-351.
    PubMed     Abstract available
    
    
    
39. ZHANG K, Chen J, Li C, Yuan Y, et al
    Exosome-mediated transfer of SNHG7 enhances docetaxel resistance in lung adenocarcinoma.
    Cancer Lett. 2022;526:142-154.
    PubMed     Abstract available
    
    
    January 2022
40. CHENG Z, Lu C, Wang H, Wang N, et al
    Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expression.
    Cancer Lett. 2022;531:1-13.
    PubMed     Abstract available
    
    
    
41. LUO F, Lu FT, Cao JX, Ma WJ, et al
    HIF-1alpha inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer.
    Cancer Lett. 2022 Jan 25. pii: S0304-3835(22)00043.
    PubMed     Abstract available
    
    
    
42. GOU W, Yu X, Wu S, Wu H, et al
    Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer.
    Cancer Lett. 2022 Jan 19. pii: S0304-3835(22)00036.
    PubMed     Abstract available
    
    
    
43. CHEN F, Liu J, Song X, DuCote TJ, et al
    EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.
    Cancer Lett. 2022;524:151-160.
    PubMed     Abstract available
    
    
    December 2021
44. CHAKRABORTY S, Utter MB, Frias MA, Foster DA, et al
    Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.
    Cancer Lett. 2021;522:164-170.
    PubMed     Abstract available
    
    
    November 2021
45. LIU S, Zhan N, Gao C, Xu P, et al
    Long noncoding RNA CBR3-AS1 mediates tumorigenesis and radiosensitivity of non-small cell lung cancer through redox and DNA repair by CBR3-AS1 /miR-409-3p/SOD1 axis.
    Cancer Lett. 2021;526:1-11.
    PubMed     Abstract available
    
    
    
46. WANG T, Liu Z, She Y, Deng J, et al
    A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis.
    Cancer Lett. 2021;520:321-331.
    PubMed     Abstract available
    
    
    
47. MEEUSEN B, Cortesi EE, Domenech Omella J, Sablina A, et al
    PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition.
    Cancer Lett. 2021;520:57-67.
    PubMed     Abstract available
    
    
    October 2021
48. GONG L, Shu J, Chen X, Pan H, et al
    DEPTOR inhibits lung tumorigenesis by inactivating the EGFR-mTOR signals.
    Cancer Lett. 2021;519:263-276.
    PubMed     Abstract available
    
    
    
49. ZHAO W, Yu D, Chen Z, Yao W, et al
    Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Cancer Lett. 2021;519:141-149.
    PubMed     Abstract available
    
    
    
50. LIANG R
    Letter to the editor regarding "XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a".
    Cancer Lett. 2021;524:193.
    PubMed    
    
    
    
51. LIU C, Xiang X, Han S, Lim HY, et al
    Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer.
    Cancer Lett. 2021;524:91-102.
    PubMed     Abstract available
    
    
    
52. ZHANG J, Wu Q, Zhu L, Xie S, et al
    SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer.
    Cancer Lett. 2021 Oct 11. pii: S0304-3835(21)00511.
    PubMed     Abstract available
    
    
    
53. DA COSTA V, van Vliet SJ, Carasi P, Frigerio S, et al
    The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2).
    Cancer Lett. 2021;518:72-81.
    PubMed     Abstract available
    
    
    
54. TINGLEI H, Biying C, Feng W, Weiyang C, et al
    Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer.
    Cancer Lett. 2021 Oct 7. pii: S0304-3835(21)00518.
    PubMed     Abstract available
    
    
    September 2021
55. YANG F, Duan M, Zheng F, Yu L, et al
    Fas signaling in adipocytes promotes low-grade inflammation and lung metastasis of colorectal cancer through interaction with Bmx.
    Cancer Lett. 2021;522:93-104.
    PubMed     Abstract available
    
    
    
56. TANIMURA K, Yamada T, Horinaka M, Katayama Y, et al
    Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.
    Cancer Lett. 2021;522:119-128.
    PubMed     Abstract available
    
    
    
57. XU Y, Chen Y, Yao Y, Xie H, et al
    VIRMA contributes to non-small cell lung cancer progression via N(6)-methyladenosine-dependent DAPK3 post-transcriptional modification.
    Cancer Lett. 2021 Sep 11. pii: S0304-3835(21)00422.
    PubMed     Abstract available
    
    
    
58. WANG J, Dai Z, Miao Y, Zhao T, et al
    Carbon ion ((12)C(6+)) irradiation induces the expression of Klrk1 in lung cancer and optimizes the tumor microenvironment based on the NKG2D/NKG2D-Ls pathway.
    Cancer Lett. 2021;521:178-195.
    PubMed     Abstract available
    
    
    August 2021
59. JIANG Y, Zhan H, Zhang Y, Yang J, et al
    ZIP4 promotes non-small cell lung cancer metastasis by activating snail-N-cadherin signaling axis.
    Cancer Lett. 2021 Aug 24. pii: S0304-3835(21)00420.
    PubMed     Abstract available
    
    
    
60. PARK MS, Yang AY, Lee JE, Kim SK, et al
    GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner.
    Cancer Lett. 2021 Aug 17. pii: S0304-3835(21)00404.
    PubMed     Abstract available
    
    
    
61. TAROMI S, Firat E, Simonis A, Braun LM, et al
    Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer.
    Cancer Lett. 2021 Aug 15. pii: S0304-3835(21)00401.
    PubMed     Abstract available
    
    
    July 2021
62. LIN S, Li Y, Wang D, Huang C, et al
    Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression.
    Cancer Lett. 2021;518:230-242.
    PubMed     Abstract available
    
    
    
63. JIN M, Li G, Liu W, Wu X, et al
    Cigarette smoking induces aberrant N(6)-methyladenosine of DAPK2 to promote non-small cell lung cancer progression by activating NF-kappaB pathway.
    Cancer Lett. 2021;518:214-229.
    PubMed     Abstract available
    
    
    
64. HUANG J, Tian F, Song Y, Cao M, et al
    A feedback circuit comprising EHD1 and 14-3-3zeta sustains beta-catenin/c-Myc-mediated aerobic glycolysis and proliferation in non-small cell lung cancer.
    Cancer Lett. 2021;520:12-25.
    PubMed     Abstract available
    
    
    June 2021
65. HAN HJ, Sung JY, Kim SH, Yun UJ, et al
    Fibronectin regulates anoikis resistance via cell aggregate formation.
    Cancer Lett. 2021;508:59-72.
    PubMed     Abstract available
    
    
    
66. ZHANG J, Zeng Y, Xing Y, Li X, et al
    Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth.
    Cancer Lett. 2021 Jun 5. pii: S0304-3835(21)00266.
    PubMed     Abstract available
    
    
    
67. GABASA M, Radisky ES, Ikemori R, Bertolini G, et al
    MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescence.
    Cancer Lett. 2021;507:1-12.
    PubMed     Abstract available
    
    
    May 2021
68. JIANG ZB, Wang WJ, Xu C, Xie YJ, et al
    Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
    Cancer Lett. 2021;515:36-48.
    PubMed     Abstract available
    
    
    
69. ZHANG H, Jiang H, Zhu L, Li J, et al
    Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives.
    Cancer Lett. 2021 May 18. pii: S0304-3835(21)00224.
    PubMed     Abstract available
    
    
    April 2021
70. WANG J, Hu T, Wang Q, Chen R, et al
    Repression of the AURKA-CXCL5 axis induces autophagic cell death and promotes radiosensitivity in non-small-cell lung cancer.
    Cancer Lett. 2021;509:89-104.
    PubMed     Abstract available
    
    
    March 2021
71. MA Y, Wang L, He F, Yang J, et al
    LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
    Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00101.
    PubMed     Abstract available
    
    
    
72. TRAVER G, Sekhar KR, Crooks PA, Keeney DS, et al
    Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC.
    Cancer Lett. 2021;500:220-227.
    PubMed     Abstract available
    
    
    February 2021
73. DANG N, Lin Y, Waer M, Sprangers B, et al
    Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
    Cancer Lett. 2021;503:151-162.
    PubMed     Abstract available
    
    
    January 2021
74. LI Y, Chen Y, Miao L, Wang Y, et al
    Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells.
    Cancer Lett. 2021;497:212-220.
    PubMed     Abstract available
    
    
    
75. LI X, Chen M, Lu W, Tang J, et al
    Targeting FAPalpha-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis.
    Cancer Lett. 2021 Jan 19. pii: S0304-3835(21)00029.
    PubMed     Abstract available
    
    
    
76. GRILLO E, Corsini M, Ravelli C, di Somma M, et al
    A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis.
    Cancer Lett. 2021;496:84-92.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: